Global 3D Printed Drugs Market Size to reach USD 342 million by 2025
New York 26 April 2018, As per a recent study conducted by Bizwit Research & Consulting LLP, Global 3D Printed Drugs Market is anticipated to grow USD 342 million by 2025. Recent approval of 3D printed drugs has created immense opportunities for pharmaceuticals and biotechnology industry in the near future. Currently, there is only one 3D printed drug, Spritam, present in the market. Spritam is a 3D printed drug launched by Aprecia Pharmaceuticals to treat epilepsy. It has received FDA approval in 2016, and is currently active only in the U.S. region.
The core objective of a 3D printed drug is to offer personalized medication to individuals in terms of dosage, size, appearance and others. The technology is also anticipated to have potential to create significant innovations in Cancer treatment, Obesity and other critical diseases. However, concerns such as blueprint hacking and mislabeling of blueprint are going to hamper the market growth. Moreover, dicey regulatory scenario is another major restraint.
To view the summary or to request a sample copy of this report, please click the link mentioned below:
Key findings of the study:
- Currently Spritam is the only 3DP drug available in the market which is available only in the U.S. region, however will likely to launch in Europe and Asia Pacific by 2022.
- Prevalence of dysphagia across the world.
- Key players in the market include Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd
Bizwit Research & Consulting LLPhas considered following segments for the study:
- Rest of the World
For more details or related reports visit our website: Bizwit Research & Consulting LLP
Or Contact US: